特発性高血圧症:治療薬開発パイプライン動向(2014年下半期)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC5264IDB)
◆英語タイトル:Idiopathic (Essential) Hypertension - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5264IDB
◆発行日:2014年7月31日
◆調査対象地域:グローバル
◆産業分野:製薬、医療
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[特発性高血圧症:治療薬開発パイプライン動向(2014年下半期)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Idiopathic (Essential) Hypertension – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension – Pipeline Review, H2 2014’, provides an overview of the Idiopathic (Essential) Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Idiopathic (Essential) Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Idiopathic (Essential) Hypertension Overview 7
Therapeutics Development 8
Pipeline Products for Idiopathic (Essential) Hypertension – Overview 8
Pipeline Products for Idiopathic (Essential) Hypertension – Comparative Analysis 9
Idiopathic (Essential) Hypertension – Therapeutics under Development by Companies 10
Idiopathic (Essential) Hypertension – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Idiopathic (Essential) Hypertension – Products under Development by Companies 15
Idiopathic (Essential) Hypertension – Companies Involved in Therapeutics Development 16
Eli Lilly and Company 16
Daiichi Sankyo Company, Limited 17
Merck & Co., Inc. 18
Novartis AG 19
Actelion Ltd 20
Forest Laboratories, Inc. 21
Les Laboratoires Servier SAS 22
Bayer AG 23
Ahn-Gook Pharmaceutical Co., Ltd. 24
PhaseBio Pharmaceuticals, Inc. 25
Lee’s Pharmaceutical Holdings Limited 26
Idiopathic (Essential) Hypertension – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 32
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
(nebivolol + valsartan) – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(perindopril + amlodipine besilate) – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(sacubitril + valsartan) – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
carvedilol – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(nifedipine + candesartan cilexetil) – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(losartan potassium + hydrochlorothiazide + amlodipine besylate) – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CS-3150 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
rostafuroxin – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ACT-280778 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LY-2623091 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PB-1046 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PB-1120 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Idiopathic (Essential) Hypertension – Recent Pipeline Updates 55
Idiopathic (Essential) Hypertension – Dormant Projects 60
Idiopathic (Essential) Hypertension – Product Development Milestones 61
Featured News & Press Releases 61
Jun 12, 2013: Lee’s Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables
Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2014 8
Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H2 2014 16
Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 17
Idiopathic (Essential) Hypertension - Pipeline by Merck & Co., Inc., H2 2014 18
Idiopathic (Essential) Hypertension - Pipeline by Novartis AG, H2 2014 19
Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H2 2014 20
Idiopathic (Essential) Hypertension - Pipeline by Forest Laboratories, Inc., H2 2014 21
Idiopathic (Essential) Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2014 22
Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H2 2014 23
Idiopathic (Essential) Hypertension - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2014 24
Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 25
Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Assessment by Combination Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H2 2014 55
Idiopathic (Essential) Hypertension - Dormant Projects, H2 2014 60

List of Figures
Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2014 8
Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 12
Assessment by Monotherapy Products, H2 2014 27
Assessment by Combination Products, H2 2014 28
Number of Products by Top 10 Target, H2 2014 29
Number of Products by Stage and Top 10 Target, H2 2014 30
Number of Products by Top 10 Mechanism of Action, H2 2014 32
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 33
Number of Products by Top 10 Route of Administration, H2 2014 35
Number of Products by Stage and Top 10 Route of Administration, H2 2014 36
Number of Products by Top 10 Molecule Type, H2 2014 37
Number of Products by Stage and Top 10 Molecule Type, H2 2014 38

*** 掲載企業 ***

Eli Lilly and Company
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Novartis AG
Actelion Ltd
Forest Laboratories, Inc.
Les Laboratoires Servier SAS
Bayer AG
Ahn-Gook Pharmaceutical Co., Ltd.
PhaseBio Pharmaceuticals, Inc.
Lee's Pharmaceutical Holdings Limited

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • PT Pertamina Geothermal Energy(電力分野):企業のM&A・提携動向
    Summary PT Pertamina Geothermal Energy (PGE) is engaged in the exploration, refinement, production and distribution of geothermal energy. PGE is state owned renewable energy company. It is subsidiary of PT Pertamina (Persero), of Indonesia. It is primarily engaged in core activities of steam supply …
  • ドライアイ症候群:ドイツ(医薬品市場予測及び分析~2022)
    PharmaPoint: Dry Eye Syndrome - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - Germany Drug Forecast and Market Analysis to 2022”. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial di …
  • 世界の3D薄型テレビ市場動向(2014~2018)
    TechNavio's analysts forecast the Global 3D Flat Panel TV market to grow at a CAGR of 15.4 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in 3D content broadcasts. The Global 3D Flat Panel TV market has also been witnessing the emergence …
  • 世界のSUAVフライトトレーニング・シミュレーション市場2016
    The Global SUAV Flight Training and Simulation Industry 2016 Market Research Report is a professional and in-depth study on the current state of the SUAV Flight Training and Simulation industry. The report provides a basic overview of the industry including definitions and classifications. The SUAV …
  • 台湾におけるモバイル買い物客の購買意向及び行動パターン
    Online shopping sites have been contributing the lion's share of global e-commerce revenues. With the growing prevalence of mobile devices, mobile commerce is anticipated to gain more ground. As a result, several e-commerce retailers have stepped up efforts to get connected to mobile devices over th …
  • 砂糖代用品の世界市場2021
    This report studies Sugar Substitutes in Global market, especially in North America, Europe, China, Japan, India and Southeast Asia, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering Ajinomoto Cargill JK Sucralose Merisant Pure …
  • 世界及び中国の2-フルオロベンジルクロリド市場2016
    The 'Global and Chinese 2-Fluorobenzyl Chloride Industry, 2016 Market Research Report' is a professional and in-depth study on the current state of the global 2-Fluorobenzyl Chloride industry with a focus on the Chinese market. The report provides key statistics on the market status of the 2-Fluorob …
  • 世界主要国におけるコンベヤーシステム市場2017-2022
    The Global Conveyor Systems market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. This report studies Conveyor Systems in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy …
  • 世界及び中国のナトリウム・マグネシウム・クロロフィリン市場2016
    The 'Global and Chinese Sodium Magnesium Chlorophyllin Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Sodium Magnesium Chlorophyllin industry with a focus on the Chinese market. The report provides key statistics on the market stat …
  • Recreational Equipment, Inc.(小売業):企業概要及びSWOT分析
    Synopsis Canadean's "Recreational Equipment, Inc.: Retailing - Company Profile & SWOT Report" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, company his …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5264IDB )"特発性高血圧症:治療薬開発パイプライン動向(2014年下半期)" (英文:Idiopathic (Essential) Hypertension - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。